FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)	ATTORNEY'S DOCKET NUMBER X-12279
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 09/763153

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US99/11969	**June 1, 1999 (06/01/99)**	**June 1, 1998 (06/01/98)**

TITLE OF INVENTION: HUMAN PROTEIN C POLYPEPTIDE

APPLICANT(S) FOR DO/EO/US: Lihua Huang and Ralph Meridith Riggin

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [ ] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] has been transmitted by the International Bureau.
   c. [X] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [ ] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] have been transmitted by the International Bureau.
   c. [X] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.
8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [ ] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [ ] Other items or information:

09763153.012001

JC02 Rec'd PCT/PTO 0 8 JAN 2001

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 09/763153	INTERNATIONAL APPLICATION NO. PCT/US99/11969	ATTORNEY'S DOCKET NUMBER X-12279

17. [X] The following fees are submitted:

	CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO..... **$840.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482)..... **$670.00**	
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... **$760.00**	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... **$970.00**	
International preliminary examination fee paid to USPTO (37 CRF 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) **$96.00**	

ENTER APPROPRIATE BASIC FEE AMOUNT =				$ 670.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than __20 __30 months from the earliest claimed priority date (37 CFR 1.492(e)).				$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	8 - 20=		**X $18.00**	$	
Independent claims	1 - 3=		**X $78.00**	$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			**+ $260.00**	$	
TOTAL OF ABOVE CALCULATIONS =				$ 670.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				$	
SUBTOTAL =				$ 670.00	
Processing fee of **$130.00** for furnishing English translation later than __ 20 __30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				$	
TOTAL NATIONAL FEE =				$ 670.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$	
TOTAL FEES ENCLOSED =				$ 670.00	
				Amount to be refunded	$
				charged	$

a. [ ] A check in the amount of $_____ to cover the above fees is enclosed.

b. [X] Please charge my Deposit Account No. 05-0840 in the amount of $ 670.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
ELI LILLY AND COMPANY
PATENT DIVISION/BPB
LILLY CORPORATE CENTER

Brian P Barrett
SIGNATURE

Brian P. Barrett
NAME

January 5, 2001
Date

39,597
REGISTRATION NUMBER

(317) 276-7243
TELEPHONE NUMBER

Human Protein C Polypeptide

The present invention is in the field of human medicine. Most specifically, the invention relates to an isolated human protein C polypeptide having a truncated heavy chain, methods of using this human protein C polypeptide, and pharmaceutical compositions of this human protein C polypeptide.

Protein C is a vitamin K dependent serine protease and naturally occurring anticoagulant that plays a role in the regulation of vascular homeostasis by inactivating Factors V_a and $VIII_a$ in the coagulation cascade. Human protein C is made primarily in the liver as a single polypeptide of 461 amino acids. This precursor molecule undergoes multiple post-translational modifications including 1) cleavage of a 42 amino acid signal sequence; 2) proteolytic removal from the one chain zymogen of the lysine residue at position 156 and the arginine residue at position 157 to make the 2-chain form of the molecule, (i.e., a light chain of 155 amino acid residues attached through a disulfide bridge to the serine protease-containing heavy chain of 262 amino acid residues); 3) vitamin K-dependent carboxylation of nine glutamic acid

residues clustered in the first 42 amino acids of the light chain, resulting in 9 gamma-carboxyglutamic acid residues; and 4) carbohydrate attachment at four sites (one in the light chain and three in the heavy chain). Finally, the circulating 2-chain zymogen is activated by the action of the thrombin/thrombomodulin complex which cleaves the activation peptide (residues 158 through 169) of the circulating zymogen producing activated protein C (aPC).

In conjunction with other proteins, protein C functions as perhaps the most important down-regulator of blood coagulation factors that promote thrombosis. Thus, the protein C enzyme system represents a major physiological mechanism of anticoagulation.

The critical role of protein C in controlling hemostasis is exemplified by the increased rate of thrombosis in heterozygous deficiency, protein C resistance (e.g., due to the common Factor V Leiden mutation) and the fatal outcome of untreated homozygous protein C deficiency. Human activated protein C, both plasma-derived and recombinant, has been shown to be an effective and safe antithrombotic agent in a variety of animal models of both venous and arterial thrombosis. Protein C in recent clinical studies has been shown to be effective in human thrombotic diseases including the treatment of protein C deficiencies and microvascular thrombosis, such as disseminated intravascular coagulation associated with sepsis.

Unfortunately, during activation of protein C, the C-terminal of the heavy chain is cleaved which has the potential to change the protein's structure, which in turn

may lead to a less elegant pharmaceutical preparation. Applicants have discovered that this truncated form of aPC is biologically active. The present invention therefore provides an isolated aPC polypeptide with a truncated heavy chain, a method to preferentially prepare this polypeptide, and its use as a medicament.

The present invention provides an isolated human protein C polypeptide comprising: a light chain and a truncated heavy chain wherein said polypeptide is SEQ ID NO: 1.

The present invention further provides a recombinant DNA molecule encoding the isolated human protein C polypeptide with a truncated heavy chain, wherein said DNA molecule is SEQ ID NO: 2.

The present invention further provides a method of treating a thrombotic disease in a patient in need thereof, which comprises, administering to said patient a pharmaceutically effective amount of an isolated human protein C polypeptide with a truncated heavy chain.

Methods and aspects of producing the isolated human protein C polypeptide with a truncated heavy chain are also an aspect of this invention.

For purposes of the present invention, as disclosed and claimed herein, the following terms are as defined below.

aPC or activated protein C whether recombinant or plasma derived - aPC includes and is preferably human protein C although aPC may also include other species or derivatives having protein C proteolytic, amidolytic,

esterolytic, and biological (anticoagulant or pro-fibrinolytic) activities. Examples of protein C derivatives are described in U.S. Patent No. 5,453,373, and U.S. Patent No. 5,516,650, the entire teachings of which are hereby included by reference.

APTT - activated partial thromboplastin time.

HPC - human protein C zymogen.

r-hPC - recombinant human protein C zymogen, produced in prokaryotic cells, eukaryotic cells or transgenic animals.

r-aPC - recombinant human activated protein C produced by activating r-hPC *in vitro* or by direct secretion of the activated form of protein C from procaryotic cells, eukaryotic cells, or transgenic animals [WO97/20043] including, for example, secretion from human kidney 293 cells as a zymogen then purified and activated by techniques well known to the skilled artisan demonstrated in U.S. Patent No. 4,981,952, and, the entire teachings of which are herein incorporated by reference.

Zymogen - refers to secreted, inactive forms, whether one chain or two chains of protein C.

Truncated heavy chain - refers to the heavy chain of protein C having its four C-terminal amino acids cleaved. For human activated protein C, the truncated heavy chain contains amino acid residues 170-415 as indicated in SEQ ID No: 1.

Light chain - refers to the light chain of protein C. For human activated protein C, the light chain contains amino acid residues 1-155 or polypeptides having one or more amino acids deleted from the C-terminus.

Thrombotic disorder - a disorder relating to, or affected with the formation or presence of a blood clot within a blood vessel. Thrombotic disorders include, but are not limited to, stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery.

Vascular occlusive disorders and hypercoagulable states: disorders including but not limited to sepsis, disseminated intravascular coagulation, purpura fulminans, major trauma, major surgery, burns, adult respiratory distress syndrome, transplantations, deep vein thrombosis, heparin-induced thrombocytopenia, sickle cell disease, thalassemia, viral hemorrhagic fever, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome

Pharmaceutical formulation - a formulation or solution that is appropriate to be given as a therapeutic agent.

Pharmaceutically effective amount as used herein, represents an amount of a compound of the invention that is capable of inhibiting a thrombotic disorder in mammals. The particular dose of the compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case, including the compound administered, the particular condition being treated, and similar considerations.

The structure of HPC is rather complex due to the number of post-translational modifications. The HPC structure consists of a light chain (residues 1-155) and a heavy chain (residues 158-419). The HPC molecule is originally expressed as a 419 amino acid polypeptide, but

prior to secretion from the cell, most of the protein is converted to the heterodimer form by removal of the Lys-Arg dipeptide at positions 156-157.

Recombinant human protein C (r-hPC) is analogous to HPC in its structure and complexity. During the conversion of r-hPC to r-aPC, thrombin selectively cleaves the activation dodecapeptide (residues 158-169). However, applicants have discovered conditions where a tetrapeptide (residues 416-419) may also cleaved from the C-terminus of the heavy chain resulting in the formation of des 416-419 aPC polypeptide. Applicants have further discovered that this form of aPC is biologically active (see Example 1, Table 1), leading to its use as a therapeutic alone or in combination with native aPC. The present invention therefore provides isolated des (416-419) aPC, a method to preferentially prepare des (416-419) aPC, and its use as a medicament

The invention also provides DNA compounds for use in making the protein C having a truncated heavy chain. These DNA compounds comprise the coding sequence for the light chain of human protein C positioned immediately adjacent to, downstream of, and in translational reading frame with the prepropeptide sequence of wild-type zymogen protein C. The DNA sequences also encode the Lys-Arg dipeptide which is processed during maturation of the protein C molecule, the activation peptide and the truncated heavy chain of the protein C molecule.

Those skilled in the art will recognize that, due to the degeneracy of the genetic code, a variety of DNA compounds can encode the activated protein C polypeptide described above. U.S. Patent No. 4,775,624, the entire

teaching of which is herein incorporated by reference, discloses and claims the DNA sequence encoding the wild-type form of the human protein C molecule. In that the skilled artisan could readily determine which changes in the DNA sequences might be used to construct the other DNA sequences which could encode the exact polypeptide as disclosed herein, the invention however is not limited to the specific DNA sequences. Consequently, the construction described below for the preferred DNA compound, vectors and transformants of the invention are merely illustrative and do not limit the scope of the invention.

The DNA compound of the present invention may be prepared by site-directed mutagenesis of the human protein C gene. The cultures are obtained and the plasmids are isolated using conventional techniques, and then may be directly transfected into eukaryotic host cells for the production of protein C with a truncated heavy chain. It is preferable to transfect the plasmids into host cells which express the adenovirus E1A immediate-early gene product, in that the BK enhancer found in the GBMT transcription control unit functions to enhance expression most efficiently in the presence of E1A. The GBMT transcription control unit is more fully described in U.S. Patent No. 5,573,938 and in European Patent Application Serial No. 91301451.0, the entire teachings of which are herein incorporated by reference. Skilled artisans realize that a number of host cells express, or can be made to express, an immediate early gene product of a large DNA virus. The most preferred cell line for expression of the human protein C derivatives of the present invention is the human kidney 293 cell line

which is disclosed in U.S. Patent No. 4,992,373, the entire teaching of which is herein incorporated by reference. After expression in the cell line, the derivatives are purified from the cell culture supernatant using the procedure in U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference.

The DNA sequence of the invention can be synthesized chemically, or by combining restriction fragments, or by a combination of techniques known in the art. DNA synthesizing machines are available and can be used to construct the DNA compounds of the present invention.

The illustrative vectors of the invention comprise the GBMT transcription unit positioned to stimulate transcription of the coding sequences by the adenovirus late promoter. Those skilled in the art recognize that a great number of eukaryotic promoters, enhancers, and expression vectors are known in the art and can be used to express the DNA sequences to produce the protein C derivatives of the present invention. Those skilled in the art also recognize that a eukaryotic expression vector can function without an enhancer element. The key aspect of the present invention resides in the novel DNA sequences and corresponding aPC with a truncated heavy chain made from those sequences.

Alternatively, the activated protein C polypeptide described herein may be prepared by reacting activated protein C with thrombin to cleave the tetrapeptide (residues 416-419) from the C-terminus of the heavy chain. The additional cleavage is obtained by exposing aPC to thrombin for an extended period, generally, 10 minutes to 3 to 5 hours under conditions appreciated in the art. aPC

polypeptides prepared by treating r-aPC with thrombin or by direct expression from eukaryotic cells have similar activity as aPC. Therefore, aPC having a truncated heavy chain will be effective in the treatment of human thrombotic diseases including replacement therapy in the treatment of protein C deficiencies, vascular occlusive disorders and hypercoagulable states including: sepsis, disseminated intravascular coagulation, purpura fulminans, major trauma, major surgery, burns, adult respiratory distress syndrome, transplantations, deep vein thrombosis, heparin-induced thrombocytopenia, sickle cell disease, thalassemia, viral hemorrhagic fever, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome as well as thrombotic disorders and disease states predisposing to thrombosis, such as, myocardial infarction and stroke, by administering an isolated human protein C polypeptide having a truncated heavy chain.

Another embodiment of the present invention is a method of treating thrombotic disorders which comprises: administering to a patient in need thereof a pharmaceutically effective amount of an isolated human protein C polypeptide having a truncated heavy chain in combination with an antiplatelet agent.

Another embodiment of the present invention is a method of treating sepsis comprising the administration to a patient in need thereof a pharmaceutically effective amount of an isolated human protein C polypeptide having a truncated heavy chain in combination with bacterial permeability increasing protein.

An isolated human protein C polypeptide having a truncated heavy chain may be formulated in a manner analogous to aPC with a pharmaceutically acceptable diluent. Preferably, including a sugar such as sucrose, salt, and a citrate buffer. Preferably, aPC derivatives are prepared at a pH of 5.5 to 6.5. Generally, pharmaceutical doses of aPC derivatives described herein will be analogous to those of native aPC, preferably 0.01 mg/kg/hr to 0.05 mg/kg/hr.

The following preparations and examples are for illustrative purposes only. One with skill in the art realizes that there are additional methods to prepare and activate recombinant protein C.

Preparation 1

Preparation of Human Protein C

Recombinant human protein C (r-HPC) is produced in Human Kidney 293 cells by techniques well known to the skilled artisan such as those set forth in U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference. The gene encoding human protein C is disclosed and claimed in U.S. Patent No. 4,775,624, the entire teaching of which is incorporated herein by reference. The plasmid used to express human protein C in 293 cells is plasmid pLPC which is disclosed in U.S. Patent No. 4,992,373 and U.S. Patent No. 5,661,002, the entire teachings of which are incorporated herein by reference. The construction of plasmid pLPC is also described in European Patent Publication No. 0 445 939, and in Grinnell, *et al.*, 1987, *Bio/Technology* 5:1189-1192, the teachings of which are also incorporated herein by reference. Briefly,

the plasmid is transfected into 293 cells, then stable transformants are identified, subcultured and grown in serum-free media. After fermentation, cell-free medium is obtained by microfiltration.

The human protein C is separated from the culture fluid by an adaptation of the techniques in U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference. The clarified medium is made 4 mM in EDTA before it is absorbed to an anion exchange resin (Fast-Flow Q, Pharmacia). After washing with 4 column volumes of 20 mM Tris, 200 mM NaCl, pH 7.4 and 2 column volumes of 20 mM Tris, 150 mM NaCl, pH 7.4, the bound recombinant human protein C zymogen is eluted with 20 mM Tris, 150 mM NaCl, 10 mM $CaCl_2$, pH 7.4. The eluted protein is greater than 95% pure after elution as judged by SDS-polyacrylamide gel electrophoresis.

Further purification of the protein is accomplished by making the protein 3 M in NaCl followed by adsorption to a hydrophobic interaction resin (Toyopearl Phenyl 650M, TosoHaas) equilibrated in 20 mM Tris, 3 M NaCl, 10 mM $CaCl_2$, pH 7.4. After washing with 2 column volumes of equilibration buffer without $CaCl_2$, the recombinant human protein C is eluted with 20 mM Tris, pH 7.4. The eluted protein is prepared for activation by removal of residual calcium. The recombinant human protein C is passed over a metal affinity column (Chelex-100, Bio-Rad) to remove calcium and again bound to an anion exchanger (Fast Flow Q, Pharmacia). Both of these columns are arranged in series and equilibrated in 20 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 7.4. Following loading of the protein, the Chelex-100

column is washed with one column volume of the same buffer before disconnecting it from the series. The anion exchange column is washed with 3 column volumes of equilibration buffer before eluting the protein with 0.4 M NaCl, 20 mM Tris-acetate, pH 6.5. Protein concentrations of recombinant human protein C and recombinant activated protein C solutions are measured by UV 280 nm extinction E0.1%=1.81 or 1.85, respectively.

Preparation 2

Activation of Recombinant Human Protein C

Bovine thrombin is coupled to Activated CH-Sepharose 4B (Pharmacia) in the presence of 50 mM HEPES, pH 7.5 at 4°C. The coupling reaction is done on resin already packed into a column using approximately 5000 units thrombin/ml resin. The thrombin solution is circulated through the column for approximately 3 hours before adding MEA to a concentration of 0.6 ml/l of circulating solution. The MEA-containing solution is circulated for an additional 10-12 hours to assure complete blockage of the unreacted amines on the resin. Following blocking, the thrombin-coupled resin is washed with 10 column volumes of 1 M NaCl, 20 mM Tris, pH 6.5 to remove all non-specifically bound protein, and is used in activation reactions after equilibrating in activation buffer.

Purified rHPC is made 5mM in EDTA (to chelate any residual calcium) and diluted to a concentration of 2 mg/ml with 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5. This material is passed through a thrombin column equilibrated at 37°C with 50 mM NaCl and either 20 mM Tris pH 7.4 or 20 mM

Tris-acetate pH 6.5. The flow rate is adjusted to allow for approximately 20 min. of contact time between the rHPC and thrombin resin. The effluent is collected and immediately assayed for amidolytic activity. If the material did not have a specific activity (amidolytic) comparable to an established standard of aPC, it is recycled over the thrombin column to activate the rHPC to completion. This is followed by 1:1 dilution of the material with 20 mM buffer as above, with a pH of either 7.4 or 6.5 to keep the aPC at lower concentrations while it awaited the next processing step.

Removal of leached thrombin from the aPC material is accomplished by binding the aPC to an anion exchange resin (Fast Flow Q, Pharmacia) equilibrated in activation buffer (either 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5) with 150 mM NaCl. Thrombin does not interact with the anion exchange resin under these conditions, but passes through the column into the sample application effluent. Once the aPC is loaded onto the column, a 2-6 column volume wash with 20 mM equilibration buffer is done before eluting the bound aPC with a step elution using 0.4 M NaCl in either 5 mM Tris-acetate, pH 6.5 or 20 mM Tris, pH 7.4. Higher volume washes of the column facilitated more complete removal of the dodecapeptide.

The anticoagulant activity of activated protein C was determined by measuring the prolongation of the clotting time in the activated partial thromboplastin time (APTT) clotting assay. A standard curve was prepared in dilution buffer (1 mg/mL radioimmunoassay grade bovine serum albumin [BSA], 20 mM Tris, pH 7.4, 150 mM NaCl, 0.02% NaN_3) ranging

in protein C concentration from 125-1000 ng/mL, while samples were prepared at several dilutions in this concentration range. To each sample cuvette, 50 μL of cold horse plasma and 50 μL of reconstituted activated partial thromboplastin time reagent (APTT Reagent, Sigma) were added and incubated at 37°C for 5 min. After incubation, 50 μL of the appropriate samples or standards were added to each cuvette. Dilution buffer was used in place of sample or standard to determine basal clotting time. The timer of the fibrometer (CoA Screener Hemostasis Analyzer, American Labor) was started immediately after the addition of 50 μL 37°C 30 mM $CaCl_2$ to each sample or standard. Activated protein C concentration in samples are calculated from the linear regression equation of the standard curve. Clotting times reported here are the average of a minimum of three replicates, including standard curve samples.

Example 1

Preparation of Des 416-419 Activated Protein C

aPC was used as the starting material to prepare des 416-419 aPC. Immobilized thrombin resin (10 mg thrombin/ml CH-Sepharose 4B resin) was used. N-glycosidase F was purchased from Boehringer Mannheim. Horse plasma is a product of Animal Technologies, Inc. (Tyler, TX). Activated CH Sepharose® 4B was bought from Pharmacia Biotech. All other chemicals were ACS reagent grade and commercially available.

A 6 mL quantity of immobilized thrombin resin was put on a 0.2 micron filter. The resin was washed with approximately 5×20 mL of 40 mM tris buffer, pH 7.02. The

washed immobilized thrombin resin was transferred to a 50 mL polypropylene vial, a 12 mL aliquot of a 2.67 mg/mL aPC solution (120 mg aPC in 45 mL of 40 mM tris buffer, pH 7.02) was added to the vial and the final volume of the suspension was adjusted to approximately 21 mL with tris buffer. The suspension was incubated at ambient temperature with constant gentle agitation. After incubation times of 10, 25, 50, 100, 160 and 240 min, 3 mL aliquots of the suspension were removed from the vial. These aliquots were centrifuged at 2000 RPM (ICE CRU-5000 Centrifuge) for 1 min. and the supernatants were transferred to several 1.5 mL polypropylene vials. These vials were immediately placed into a dry ice bath to freeze the solution. A control sample was prepared at the same time using de-activated CH-Sepharose 4B resin which did not contain immobilized thrombin.

Protein Content Assay. Aliquots (150 mcL) of the sample solution was diluted with 450 mcL of 40 mM tris buffer, pH 7.02 or reagent water. The sample cell was rinsed twice with the sample solution and the UV absorbance (at λ=280 nm) of the solution was measured. Tris buffer or reagent water was used as the blank for this measurement.

LC/MS Assay for Protein Polypeptide Distribution. Aliquots of approximately 600 mcL of the sample solution were mixed with 240 mg urea, 80 mcL of 3 M tris buffer (pH = 8.0) and 15 mcL of 50 mg/mL dithiothreitol solution and the mixture was incubated at 37°C for 30 min. The sample was alkylated by adding 50 mcL of 50 mg/mL iodoacetamide solution and incubating at ambient temperature in the dark for 30 min. Samples were then desalted on a disposable gel

filtration column, deglycosylated with N-glycosidase F and analyzed by LC/MS .

RP-HPLC Assay. Three hundred to four hundred microliter aliquots of the thawed sample solution were mixed with a sufficient volume of 0.1% TFA solution to obtain an approximately 1 mg/mL solution. This solution was used as the high concentration sample. The low concentration sample was prepared by mixing 50 mcL aliquots of the high concentration sample with 450 mcL of 0.1% TFA solution. One hundred microliter aliquots of each high and low concentration sample were injected onto the HPLC system.

APTT Assay. The sample was assayed on an Automated Activated Partial Thromboplastin Time (APTT) CoaLab Analyzer. All samples were diluted using manual pipettes to final concentrations between 410 ng and 420 ng aPC/mL. An aPC reference standard having an assigned potency of 303 U/mg, was used for this assay. Des (416-419) aPC generated as described above has similar biological activity to that of native aPC as measured by the APTT assay. The relationship between APTT anticoagulant activity and percent of Des 416-419 aPC is shown in Table 1. The percent of Des 416-419 aPC may be as high as 68% and still maintains essentially the same anticoagulant activity as native aPC. In general, aPC made by the methods described herein contain from about 1% to about 25% Des 416-419 aPC.

Table 1

Incubation Time (min)	Percent (%) of Des 416-419 aPC		APTT Activity (U/mg)	
	Control	Sample	Control	Sample
t = 0	13	-	512	-
t = 10	14	20		503
t = 25	14	26		533
t = 50	14	35		530
t = 100	14	46		521
t = 160	14	57		509
t = 240	13	68		509

What is Claimed is:

1. An isolated human protein C polypeptide comprising: a light chain and a truncated heavy chain.

2. The polypeptide of claim 1 wherein said polypeptide is SEQ ID NO: 1.

3. A recombinant DNA molecule encoding the human protein C polypeptide of Claim 1.

4. The recombinant DNA molecule of Claim 3, wherein said DNA molecule is SEQ ID NO: 2.

5. The isolated human protein C polypeptide of Claim 1, wherein said human protein C polypeptide is activated.

6. A method of treating thrombotic disorders, vascular occlusive disorders and hypercoagulable states in a patient in need thereof, which comprises: administering to said patient a pharmaceutically effective amount of an isolated activated protein C polypeptide with a truncated heavy chain of Claim 1.

7. A vector, comprising a nucleic acid according to Claim 2.

8. A host cell comprising an isolated nucleic acid according to Claim 2.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 9/64, 15/00, 15/57, 15/70, 15/79

A1

(11) International Publication Number: WO 99/63070

(43) International Publication Date: 9 December 1999 (09.12.99)

(21) International Application Number: PCT/US99/11969

(22) International Filing Date: 1 June 1999 (01.06.99)

(30) Priority Data:
60/087,585 1 June 1998 (01.06.98) US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HUANG, Lihua [CN/US]; 12138 Penneagle Drive, Carmel, IN 46033 (US). RIGGIN, Ralph, Meridith [US/US]; 708 Suffolk Lane, Carmel, IN 46032 (US).

(74) Agents: BARRETT, Brian, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: HUMAN PROTEIN C POLYPEPTIDE

(57) Abstract

An isolated human protein C polypeptide with a truncated heavy chain is described. This isolated polypeptide retains the biological activity of the wild-type human protein C. This polypeptide will be useful in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

Please type a plus sign (+) inside this box [+]

09/263,153 PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

[X] Declaration Submitted with Initial Filing
[ ] Declaration Submitted after Initial Filing

Attorney Docket Number	**X-12279**
First Named Inventor	**Lihua Huang, et al.**
COMPLETE IF KNOWN	
Application Number	
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HUMAN PROTEIN C POLYPEPTIDE

the specification of which
[ ] is attached hereto
OR
[X] was filed on (MM/DD/YYYY) 01 June 1999 as United States Application Number or PCT International Application Number PCT/US99/11969 and was amended on (MM/DD/YYYY) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached YES	NO
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]

[ ] Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional applications(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/087,585	01 June 1998	[ ] Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

Please type a plus sign (+) inside this box [+]

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

55

Attorney Name	Reg. No.
Arvie J. Anderson	45,263
Lynn D. Apelgren	P45,341
Robert A. Armitage	27,417
Brian P. Barrett	39,597
Michael T. Bates	34,121
Roger S. Benjamin	27,025
William R. Boudreaux	35,796
Steven P. Caltrider	36,467
Paul R. Cantrell	36,470
Charles E. Cohen	34,565
Kenneth J. Collier	34,982
Daniel W. Collins	31,912
Robert A. Conrad	32,089
Elizabeth A. Dawalt	44,646
Paul R. Darkes	33,862
Steven G. Davis	39,652
John C. Demeter	30,167
Manisha A. Desai	43,585
John H. Engelmann	28,075
Joanne Longo Feeney	35,134
Paul J. Gaylo	36,808
Francis O. Ginah	44,712
Edward P. Gray	30,638
Amy E. Hamilton	33,894
Suzanne M. Harvey	42,640
Frederick D. Hunter	26,915
Thomas E. Jackson	33,064
Charles Joyner	30,466
James J. Kelley	41,888

Attorney Name	Reg. No.
Paul C. Kimball	34,641
Paul J. Koivuniemi	31,533
Robert E. Lee	27,919
James P. Leeds	35,241
Nelsen L. Lentz	38,537
Ronald S. Maciak	35,262
Janet T. McClain	36,863
Scott A. McNeil	37,185
Arlene K. Musser	37,895
Douglas K. Norman	33,267
Arleen Palmberg	40,422
Raymond S. Parker, III	34,893
Thomas G. Plant	35,784
James J. Sales	33,773
Michael J. Sayles	32,295
Robert L. Sharp	P45,609
David M. Stemerick	40,187
Mark J. Stewart	43,936
Robert D. Titus	40,206
Tina M. Tucker	P47,145
MaCharri Vorndran-Jones	36,711
Gilbert T. Voy	43,972
Andrea C. Walsh	34,988
Thomas D. Webster	39,872
Lawrence T. Welch	29,487
Alexander Wilson	P45,782

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name	ELI LILLY AND COMPANY						
Address	ATTN: PATENT DEPARTMENT						
Address	LILLY CORPORATE CENTER/DC1104						
City	INDIANAPOLIS	State	INDIANA		ZIP	46285	
Country	USA	Telephone	(317) 276-6015		Fax	(317) 276-3861	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A Petition has been filed for this unsigned inventor

Given Name	Lihua	Middle Initial		Family Name	Huang	Suffix e.g. Jr.	
Inventor's Signature	Lihua Huang					Date	10/4/2000
Residence: City	Carmel	State	IN	Country	US	Citizenship	CN
Address	12138 Penneagle Drive						
Post Office Address	SAME AS ABOVE						
City	Carmel	State	IN	Zip	46033	Country	US

☐ Additional Inventors are being named on supplement sheet(s) attached hereto.

Please type a plus sign (+) inside this box [+]

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

Name of Additional Joint Inventor, if any: 2 of 2				☐ A Petition has been filed for this unsigned inventor			
Given Name	Ralph	Middle Initial	M	Family Name	Riggin	Suffix e.g. Jr.	
Inventor's Signature	Ralph Merrill Riggin				Date	10-Nov-2000	
Residence: City	Carmel	State	IN	Country	US	Citizenship	US
Address	708 Suffolk Lane						
Post Office Address	SAME AS ABOVE						
City	Carmel	State	IN	Zip	46033	Country	US

SEQUENCE LISTING

<110> Eli Lilly and Company

<120> Protein C polypeptide

<130> protein C truncated heavy chain

<140> x12279
<141> 1999-06-02

<160> 2

<170> PatentIn Ver. 2.0

<210> 1
<211> 1244
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: recombinant
human protein C truncated at C-terminus

<400> 1
gccaactcct tcctggagga gctccgtcac agcagcctgg agcgggagtg catagaggag 60
atctgtgact tcgaggaggc caaggaaatt ttccaaaatg tggatgacac actggccttc 120
tggtccaagc acgtcgacgg tgaccagtgc ttggtcttgc ccttggagca cccgtgcgcc 180
agcctgtgct gcgggcacgg cacgtgcatc gacggcatcg gcagcttcag ctgcgactgc 240
cgcagcggct gggagggccg cttctgccag cgcgaggtga gcttcctcaa ttgctcgctg 300
gacaacggcg gctgcacgca ttactgccta gaggaggtgg gctggcggcg ctgtagctgt 360
gcgcctggct acaagctggg ggacgacctc ctgcagtgtc accccgcagt gaagttccct 420
tgtgggaggc cctggaagcg gatggagaag aagcgcagtc acctgaaacg agacacagaa 480
gaccaagaag accaagtaga tccgcggctc attgatggga agatgaccag gcggggagac 540
agcccctggc aggtggtcct gctggactca aagaagaagc tggcctgcgg ggcagtgctc 600
atccaccct cctgggtgct gacagcggcc cactgcatgg atgagtccaa gaagctcctt 660
gtcaggcttg gagagtatga cctgcggcgc tgggagaagt gggagctgga cctggacatc 720
aaggaggtct tcgtccaccc caactacagc aagagcacca ccgacaatga catcgcactg 780
ctgcacctgg cccagcccgc caccctctcg cagaccatag tgcccatctg cctcccggac 840
agcggccttg cagagcgcga gctcaatcag gccggccagg agaccctcgt gacgggctgg 900
ggctaccaca gcagccgaga gaaggaggcc aagagaaacc gcaccttcgt cctcaacttc 960
atcaagattc ccgtggtccc gcacaatgag tgcagcgagg tcatgagcaa catggtgtct 1020
gagaacatgc tgtgtgcggg catcctcggg gaccggcagg atgcctgcga gggcgacagt 1080
gggggggcca tggtcgcctc cttccacggc acctggttcc tggtgggcct ggtgagctgg 1140
ggtgagggct gtgggctcct tcacaactac ggcgtttaca ccaaagtcag ccgctacctc 1200
gactggatcc atgggcacat cagagacaag gaagcccccc agaag 1245

<210> 2

<211> 415
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: recombinant human protein C amino acid sequence with C-terminus truncation

<400> 2

Ala	Asn	Ser	Phe	Leu	Glu	Glu	Leu	Arg	His	Ser	Ser	Leu	Glu	Arg	Glu
1				5					10					15	
Cys	Ile	Glu	Glu	Ile	Cys	Asp	Phe	Glu	Glu	Ala	Lys	Glu	Ile	Phe	Gln
			20					25					30		
Asn	Val	Asp	Asp	Thr	Leu	Ala	Phe	Trp	Ser	Lys	His	Val	Asp	Gly	Asp
		35					40					45			
Gln	Cys	Leu	Val	Leu	Pro	Leu	Glu	His	Pro	Cys	Ala	Ser	Leu	Cys	Cys
	50					55					60				
Gly	His	Gly	Thr	Cys	Ile	Asp	Gly	Ile	Gly	Ser	Phe	Ser	Cys	Asp	Cys
65					70					75					80
Arg	Ser	Gly	Trp	Glu	Gly	Arg	Phe	Cys	Gln	Arg	Glu	Val	Ser	Phe	Leu
				85					90					95	
Asn	Cys	Ser	Leu	Asp	Asn	Gly	Gly	Cys	Thr	His	Tyr	Cys	Leu	Glu	Glu
			100					105					110		
Val	Gly	Trp	Arg	Arg	Cys	Ser	Cys	Ala	Pro	Gly	Tyr	Lys	Leu	Gly	Asp
		115					120					125			
Asp	Leu	Leu	Gln	Cys	His	Pro	Ala	Val	Lys	Phe	Pro	Cys	Gly	Arg	Pro
	130					135					140				
Trp	Lys	Arg	Met	Glu	Lys	Lys	Arg	Ser	His	Leu	Lys	Arg	Asp	Thr	Glu
145					150					155					160
Asp	Gln	Glu	Asp	Gln	Val	Asp	Pro	Arg	Leu	Ile	Asp	Gly	Lys	Met	Thr
				165					170					175	
Arg	Arg	Gly	Asp	Ser	Pro	Trp	Gln	Val	Val	Leu	Leu	Asp	Ser	Lys	Lys
			180					185					190		
Lys	Leu	Ala	Cys	Gly	Ala	Val	Leu	Ile	His	Pro	Ser	Trp	Val	Leu	Thr
		195					200					205			

Ala Ala His Cys Met Asp Glu Ser Lys Lys Leu Leu Val Arg Leu Gly
210 215 220

Glu Tyr Asp Leu Arg Arg Trp Glu Lys Trp Glu Leu Asp Leu Asp Ile
225 230 235 240

Lys Glu Val Phe Val His Pro Asn Tyr Ser Lys Ser Thr Thr Asp Asn
245 250 255

Asp Ile Ala Leu Leu His Leu Ala Gln Pro Ala Thr Leu Ser Gln Thr
260 265 270

Ile Val Pro Ile Cys Leu Pro Asp Ser Gly Leu Ala Glu Arg Glu Leu
275 280 285

Asn Gln Ala Gly Gln Glu Thr Leu Val Thr Gly Trp Gly Tyr His Ser
290 295 300

Ser Arg Glu Lys Glu Ala Lys Arg Asn Arg Thr Phe Val Leu Asn Phe
305 310 315 320

Ile Lys Ile Pro Val Val Pro His Asn Glu Cys Ser Glu Val Met Ser
325 330 335

Asn Met Val Ser Glu Asn Met Leu Cys Ala Gly Ile Leu Gly Asp Arg
340 345 350

Gln Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Met Val Ala Ser Phe
355 360 365

His Gly Thr Trp Phe Leu Val Gly Leu Val Ser Trp Gly Glu Gly Cys
370 375 380

Gly Leu Leu His Asn Tyr Gly Val Tyr Thr Lys Val Ser Arg Tyr Leu
385 390 395 400

Asp Trp Ile His Gly His Ile Arg Asp Lys Glu Ala Pro Gln Lys
405 410 415